SCHEMBL2185159

SCHEMBL2185159

CC1(C)C(=O)N(C2C3CC4CC(C3)CC2C4)N1C(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
RBP4 P02753 1/20 0.41
CES2 O00748 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD11B1 P28845 2/20 0.39
MGLL Q99685 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
CHRM5 P08912 1/20 0.38
TP53 P04637 1/20 0.37
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
AR P10275 1/20 0.37
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2169795 0.89 HIF1A (0.39) CES2
SCHEMBL2168658 0.86 PLA2G7 (0.41) LMNAHPGDMEN1KMT2AALDH1A1
SCHEMBL2168963 0.84 ALDH1A1 (0.43) HPGDKMT2AALDH1A1TP53NPSR1
SCHEMBL2169563 0.84 P2RX7 (0.40) MEN1KMT2AALDH1A1HSD11B1MGLL
SCHEMBL2169090 0.83 USP2 (0.51) KMT2AALDH1A1HSD11B1
SCHEMBL2168721 0.82 KMT2A (0.46) HPGDCES2MEN1KMT2AALDH1A1
SCHEMBL13368861 0.79 RBP4 (0.40) LMNAPOLBHPGDRBP4CES2
SCHEMBL2169157 0.79 MEN1 (0.40) HPGDMEN1KMT2AALDH1A1HSD11B1
SCHEMBL2169109 0.78 CYP2C9 (0.38) LMNAHSD11B1MGLLTP53MAPT
SCHEMBL2170075 0.78 CHRNA7 (0.41) HPGDKMT2AALDH1A1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 LMNA 2658/4885POLB 3701/4885HPGD 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.